A culture medium for culturing Clostridium difficile under aerobic culture conditions, the medium includes a nutrient medium that promotes growth of Clostridium difficile and amounts of thioglycolic and L-cystine effective to consume oxygen in the culture medium and facilitate growth of Clostridium difficile.

The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis and the design of personalized, targeted therapies.

The present invention provides a pharmaceutical composition comprising an antibody which binds to human PRDX4 present on the cell surface of a target cell and optionally a pharmaceutically acceptable carrier, diluent or excipient. The present invention further provides said pharmaceutical composition for use in a method for the treatment of cancer in a human subject. Further is provided a method for determining whether a human subject may suffer from cancer, comprising determining in a sample obtained from said human subject whether PRDX4 is present on the cell surface of cells comprised by said sample. Additionally, an antibody which binds to human PRDX4 present on the cell surface of a target cell is provided.

Disclosed are compositions and methods for inactivating one or more enzymes in a biological sample.

The present invention relates to a specific set of circulating protein and metabolite biomarkers for the diagnosis of Brugada Syndrome (BrS) in a human being and relative methods of detection. The invention further relates to mutated Prg4, Epx and Pon1 genes and related proteins for the prediction and diagnosis of Brugada Syndrome.

Disclosed are target for screening anti-tumor drug, application use thereof and screening method therefor. Disclosed are a target for screening a drug for treating and/or preventing tumors, the target for screening the drug for treating and/or preventing tumors comprise selenoprotein; and a target for screening a drug for preventing tumor metastasis, the target for screening the drug for preventing the tumor metastasis comprising selenoprotein. Also disclosed is a method for screening a drug for treating and/or preventing tumors or a drug for preventing tumor metastasis, the method comprising: interacting a candidate drug with the selenoprotein; and screening the drug for treating and/or preventing tumors or the drug for preventing tumor metastasis according to an affinity between the candidate drug and the selenoprotein; and the candidate drug with a high affinity with the selenoprotein is taken as a candidate primarily screened drug.

Disclosed in the present application are: (i) a compound inhibiting the interaction between LSD1me2 and CHD1 for use in therapy, (ii) a compound inhibiting the interaction between LSD1me2 and CHD1 for use in treating cancer, in particular prostate cancer, and (iii) a method of screening for such a compound.

The invention disclosed herein includes amperometric glucose sensors having electrodes formed from processes that electrodeposit platinum black in a manner that produces relatively smooth three dimensional metal architectures, ones that contribute to sensor reliability and stability. Embodiments of the invention provide analyte sensors having such uniform electrode architectures as well as methods for making and using these sensor electrodes. A number of working embodiments of the invention are shown to be useful in amperometric glucose sensors worn by diabetic individuals.

The present invention relates to an inhibitor of glycerol-3-phosphate dehydrogenase 1 (GPD1 inhibitor) for use in treatment and/or prevention of cancer. The present invention further relates to a kit comprising a GPD1 inhibitor comprised in a housing; to a method for identifying a subject suffering from cancer susceptible to cancer treatment by administration of a GPD1 inhibitor comprising a) determining in a sample of said subject the amount of a GPD1 gene product, b) comparing said amount determined in step a) to a reference, and c) based on the result of step b), identifying a subject susceptible to cancer treatment by administration of a GPD1 inhibitor; and to further means and methods related thereto.

The present disclosure provides methods, compositions and kits for measuring activity of a frataxin (FXN) protein, e.g., an FXN fusion protein. The present invention also provides methods for identifying compounds capable of modulating activity of an FXN protein, e.g., an FXN fusion protein.